Loading…
← CockpitCompetitor Analysis › 2526.HK Hangzhou Diagens Biotechnology Co., Ltd. Class HOpen in the cockpit ↗

Hangzhou Diagens Biotechnology Co., Ltd. Class H2526.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Information Technology›Packaged Software

Hangzhou-based biotechnology company likely focused on molecular diagnostics or genetic testing; specific business not confirmed with confidence.

Momentum laggard 1
Mkt cap
$1.11B
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$5.20M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-50.8 pp
WACC 15.0%
Hurdle
n/a
no reverse DCF
Close · HKDHK$100.80
1D-5.5%
1W+10.0%
1M-54.8%
3M-69.6%
6M-67.0%
YTDn/a
1Yn/a
ATR %24.1%
52w lowhigh86.8% off high

What Hangzhou Diagens Biotechnology does

Hangzhou-based biotechnology company likely focused on molecular diagnostics or genetic testing; specific business not confirmed with confidence.

Where it sits in the supply chain

  • Health Care
  • Diagnostics/biotechnology

Moat: none

Headquarters: Hangzhou, China · Employees: 166

Hangzhou Diagens Biotechnology at a glance

Size Hangzhou Diagens Biotechnology (2526.HK) is a Hong Kong Information Technology company (Packaged Software) with a market value of $1.11B, the 558th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$100.80 on 18 Nov 2026.

Performance Over six months the shares fell 67.0%, against -19.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 133.8% over the last twelve months (peer median +19.2%); the operating margin is -49.0% (peer median 6.2%).

Valuation It trades at 44.7× enterprise value to sales against a peer median of 3.8× (most expensive of 21).

Capital Return on invested capital runs 50.8 points below its cost of capital (15.0% WACC).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026Peer median 812526.HK 34
Six months, rebased to 100: Hangzhou Diagens Biotechnology against the median of its 20 peers (local-currency closes).

Hangzhou Diagens Biotechnology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenuen/aHK$178MHK$76.3MHK$58.4M
Revenue growth—+134%+31%—
Gross profitn/aHK$128MHK$49.9MHK$41.4M
EBITDAn/a-HK$75.4M-HK$20.0M-HK$40.5M
Net incomen/a-HK$72.8M-HK$47.0M-HK$62.0M
Free cash flown/a-HK$62.3M-HK$57.4M-HK$79.4M
Capital expendituren/aHK$8.27MHK$27.4MHK$26.8M
Total debtn/aHK$6.59MHK$20.4MHK$315M

Quarterly statements and history in the cockpit →

Hangzhou Diagens Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-60%-40%-20%0%RSKD300031688031462870300766RDVT03540800VIT-B3015632492000676EVCM68822774SW44786030822526.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Hangzhou Diagens Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×RSKD300031688031462870300766RDVT03540800VIT-B00067630138268822726723006342526.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hangzhou Diagens Biotechnology is the large dot.

Hangzhou Diagens Biotechnology competitors and peer comparison

How Hangzhou Diagens Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hangzhou Diagens Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure2526.HKPeer medianRank in peer set
1-month return-54.8%-10.2%2nd lowest of 21
6-month return-67.0%-19.8%lowest of 20
Distance from 52-week high-86.8%-44.3%lowest of 21
Revenue growth (TTM)+133.8%+19.2%highest of 21
Operating margin-49.0%6.2%3rd lowest of 21
EV / Sales44.7×3.8×most expensive of 21
ROIC minus cost of capital-50.8 pp-1.1 pp2nd lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hangzhou Diagens Biotechnology 2526.HKHong Kong$1.11B-67%+134%-49%44.7×n/an/a
Riskified RSKDUnited States$1.11B+100%+18%-3%2.2×12.0%+15.3%
Wuxi Boton Technology 300031.SZChina$1.11B-20%+22%2%1.9×23.6%+5.6%
Transwarp Technology Shanghai 688031.SSChina$1.09B-51%+27%-49%13.3×n/an/a
SHIFT UP 462870.KSSouth Korea$1.13B-21%-27%50%4.7×-12.0%+59.7%
Merit Interactive 300766.SZChina$1.08B-36%+30%-2%11.4×n/an/a
Red Violet RDVTUnited States$1.14B+43%+20%18%10.0×38.3%+21.1%
Chinasoft International 0354.HKHong Kong$1.07B-5%+3%2%0.6×16.9%+3.1%
WeRide 0800.HKHong Kong$1.14B-44%+109%-221%3.7×n/an/a
Vitec Software VIT-B.STSweden$1.15B+5%+6%21%3.9×3.7%+22.6%
ICkey (Shanghai) Internet & Technology 301563.SZChina$1.06B-35%+26%9%1.4×n/an/a
Infomart 2492.TJapan$1.15B+78%+11%19%8.2×12.6%+16.5%
Genimous Technology 000676.SZChina$1.15B-11%+3%6%1.5×11.8%-17.5%
EverCommerce EVCMUnited States$1.06B-42%-2%13%2.4×8.1%+11.8%
Fengzhushou 301382.SZChina$1.16B-42%+28%8%3.8×n/an/a
Bingo Software 688227.SSChina$1.17B-29%-7%-11%15.6×n/an/a
Baige Online Digital Technology 2672.HKHong Kong$1.18Bn/a+34%-3%6.5×53.3%+41.4%
74Software 74SW.PAFrance$1.03B-15%+11%14%1.6×-2.1%+18.9%
freee K.K 4478.TJapan$1.19B+50%+26%4%3.9×41.6%+32.8%
BZS (Beijing) Technology Development 603082.SSChina$1.02B-4%+22%6%2.5×21.2%+13.7%
Richinfo Technology 300634.SZChina$1.19B-24%-11%10%4.4×19.2%+19.9%

Questions

Which companies are Hangzhou Diagens Biotechnology's closest peers?
The cockpit's peer set: Riskified (RSKD), Wuxi Boton Technology (300031.SZ), Transwarp Technology Shanghai (688031.SS), SHIFT UP (462870.KS), Merit Interactive (300766.SZ), Red Violet (RDVT), Chinasoft International (0354.HK), WeRide (0800.HK).
Is Hangzhou Diagens Biotechnology expensive compared with its peers?
On ev / sales it trades at 44.7× against a peer median of 3.8×, most expensive of 21 in its peer set.
How has Hangzhou Diagens Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -67.0% against -19.8% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.